Floatz logo

Rosuvastatin

Head Injury

Universidad Autonoma de San Luis PotosíSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Head Injury cohort.

Asset / SponsorPhaseRating
Aspirin
Hadassah Medical Organization
Phase 4BB
Oxygen
Jay C. Buckey Jr.
Phase 4BB
Sodium Lactate
Institut d'Anesthesiologie des Alpes Maritimes
Phase 2/3B
Sufentanyl
Pierre-Julien CUNGI
Phase 2CCC
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Pierre-Julien CUNGI
Phase 2CCC
Mannitol
Massachusetts General Hospital
Phase 1/2CCC
Nepenthe
Dalhousie University
Phase 1/2CCC
Red Blood Cells
ThermoFisher Scientific Brahms Biomarkers France
N/AD

Same molecule, other indications

Rosuvastatin is also rated in:

inherited lipid metabolism disorderActive
A
Indicative · Phase 4
81 / 100
View asset →
hyperlipidemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
cardiovascular disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →